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Abstract
  
 The incidence of Breast Cancer Metastasis (MBC) can be categorized in stage IV 
as well as being the leading cause of death in cases of breast cancer. MBC prognosis 
is known to be weak, frequent recurrent, and MBC patients have only a survival rate 
of about 5 years. One of the proteins that causes breast cancer metastasis is Human 
Epidermal Growth Factor 2 (HER2). Pentagamaboron-0 (PGB-0), a newly curcumin 
analogue performed cytotoxic effect on HER2-positive breast cancer cells but it is 
practically water-insoluble. The aims of this study are to determine anti-metastatic 
activity of a more soluble form of PGB-0 namely PGB-0 fructose complex (PGB-0-F) 
toward HER2 positive cancer (MCF-7/HER2) cells. PGB-0-F was obtained from Cancer 
Chemoprevention Research Centre Faculty of Pharmacy Universitas Gadjah Mada. Based 
on scratch wound healing assay result, PGB-0-F inhibited cell migration especially in 
combination with doxorubicin at the concentration 15 µM. Under gelatin zymography 
assay, PGB-0-F in combination with doxorubicin decreased Matrix Metalloproteinases 9 
(MMP-9) expression compare to the doxorubicin. Hence, PGB-0-F has a potency to be 
developed as anti-metastatic agent  on HER2 overexpression breast cancer.
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INTRODUCTION
 Breast cancer is one of the most common types 
of cancer suffered by women (Ferlay, et al., 2012). 
Breast cancer was first as the most common cancer 
of women and the second leading cause of death 
due to cancer in women (Shiegel, et al., 2018). In 
Indonesia breast cancer ranks first with a percentage 
of 43.3% as a cancer that affects many women and 
causes at least 12.9% of deaths in women due to 
cancer (Kemenkes RI, 2015).
 Breast cancer in the presence of excessive 
expression of Human Epidermal Growth Factor 2 
(HER2) receptors is known to have a fairly high 
prevalence. It was reported that about 21% of 272 
cases of breast cancer in 2006-2007 in Hong Kong 
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were breast cancer with overexpression of HER2 
(Yau, et al., 2008). In addition, 44.5% of breast 
cancer over HER2 expression was also found from 
3,033 breast cancer patients in Iran (Keyhani, et al., 
2010). Over-expression of HER2 in breast cancer 
can affect malignancy rates, affect metastasis and 
lead to uncontrolled growth of cancer cells (Gibbs, 
2000; Lemmen, et al., 2004; Freudenberg, et al., 
2009).
 Metastasis can be interpreted as a process of 
transfer of cancer cells from the primary to other 
organs located far from the primary place (Scully, 
et al., 2012). Incidence of Breast Cancer Metastasis 
(MBC) can be categorized in stage IV as well as 
being the leading cause of death in cases of breast 
cancer. About 5% of patients diagnosed with breast 
cancer are MBC. MBC prognosis is known to be 
weak, recurrent is common, and MBC patients have 
only a survival rate of about 5 years (Donovan, 2013). 
In addition, therapy on MBC is purely palliative, 
i.e., reducing symptoms, improving quality of life, 
lengthening survival time, and preventing cancer 
progression (O'Shaughnessy, 2005). 
 The treatment of breast cancer that is still in 
use today is based on the presence of excessive 
expression in protein markers such as estrogen 
receptor (ER), progesterone receptor (PgR) and also 
HER2 (Furuya, et al., 2012). Systemic treatments 
include the use of chemotherapy agents, hormonal 
agents and immunotherapy agents. The use of these 
three agents will initially give positive results in 
90% of cases of breast cancer and 50% in cases 
of metastasis (Gonzalez-Angulo, 2013). However, 
intensive use leads to cancer resistance and new 
treatments are needed to address this problem.
 Curcumin is a major component of turmeric 
that has been known to have strong cytotoxic activity 
so widely used as a lead compound for the discovery 
of new drugs (Figure 1). Some curcumin analogues 
have been previously known to have activities that 
are either anticancer agents or co-chemotherapy. 
Pentagamavunon-1 (PGV-1) had cytotoxic activity 
in WiDr cancer cells through apoptosis pathways 
(Meiyanto, et al., 2016) and was able to reduced 
the expression of angiogenesis factors (VEGF and 
COX-2) in estrogen-induced T474 cancer cells 
(Meiyanto, et al., 2006) Pentagamavunon-0 (PGV-
0) also has antiproliferation activities in HeLa 
cells (Meiyanto, et al., 2003), T47D breast cancer 
cells (Meiyanto, et al., 2006) through induction of 
apoptosis from the caspase-3 pathway (Meiyanto, et 
al., 2007). Modification of PGV-0 with Potassium 
(K-PGV-0) also results in apoptosis and cell cycle 
induction, and antimigration of triple negative 4T1 
breast cancer cells in combination with doxorubicin 
(Herwandhani, et al., 2016)
Figure 1. Chemical Structure of Curcumin (A), PGB-0 (B) and PGB-0-F (C).
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 One of the new curcumin analogues developed 
by Cancer Chemoprevention Research Centre 
Faculty of Pharmacy Universitas Gadjah Mada 
(CCRC-FF-UGM) is Pentagammaboron-0 (PGB-
0). In addition to being a chemotherapy agent, 
PGB-0 also acts as a boron carrying agent that can 
be used as targeted chemotherapy. PGB-0 is known 
to have cytotoxic activity in some cancer cells but 
has a water-insoluble nature. Recent study reveals 
that PGB-0 have cytotoxic activity on MCF-7/
HER2 breast cancer cells by modulated cell cycle 
in G1 phase. This activity is thought to be caused 
by binding of PGB-0 in the tyrosine kinase part 
of HER2 as evidenced by a decrease in HER2 
expression in PGB-0 treatment (Utomo, et al., 
2017). PGB-0 in combination with doxorubicin 
also showed antimigration by decreased the MMP-
9 expression on 4T1 cells (CCRC unpublised data). 
Recent research has succeeded in making a complex 
between PGB-0 with fructose (PGB-0-F) which 
increases solubility of PGB-0. Increased solubility 
may increase uptake so as to also increase cytotoxic 
activity of PGB-0.
 This study is intended to examine the solute 
complex capability of PGB-0 (PGB-0-F) as novel 
anti-metastasis agents on MCF-7/HER2 breast 
cancer cells. MCF-7/HER2 cells was used as a 
model of HER2 overexpression of breast cancer 
cells. Possible antimetastasis effect of PGB-0 was 
measured by scratch wound healing assay and 
gelatin zymograph. The result of this study will 
be used for further experiment in order to develop 
novel anti-metastasis agents from PGB-0-F.
MATERIALS AND METHODS
Materials
 PGB-0-F was obtained from CCRC-FF-UGM. 
Doxorubicin was purchased from sigma.
Cell Culture
 MCF-7/HER2 breast cancer cells stored in 
CCRC-FF-UGM was obtained from Prof. Kawaichi, 
Nara Institute of Science and Technology, Japan .The 
culture of MCF-7/HER2 cells was grown on a high 
glucose culture medium Dulbecco's Modified Eagle 
Media (DMEM) (Gibco, Invitrogen, Massachusetts 
USA) containing 10% Fetal Bovine Serum (FBS) 
(Sigma-Aldrich, Missouri, USA), 1.5% penicillin-
streptomycin (Gibco) and 0.5% Fungizone (Gibco). 
Cells harvesting from Tissue Culture Dish (Iwaki, 
Kuala Lumpur, Malaysia) using 0.25% trypsin-
EDTA (Gibco).
Scratch Wound Healing Assay
 A total of 8.5 x 104 MCF-7/HER2 cells were 
distributed into 24 well plates, then incubated for 
24 hours at 37°C, 5% CO2 Cells were washed using 
PBS 1x and given starvation medium (a culture 
medium with 0.5% FBS) then incubated for 24 
hours was. Each well then scratched vertically by 
using yellow tip and treated with PGB-0-F with 
concetration of 15, 7.5,  and 3.75 µM and 10 nM 
Doxorubicin and their combinations. Cells were 
observed under a light microscope each time 0, 18, 
24, and 42 hours and captured by digital camera 
(Samsung, Seoul, Korea).
Gelatin Zymography Assay
 A total of 2 x 105 MCF-7/HER2 cells were 
planted in a 6-well plate with 2 mL of culture 
medium and incubated for 24 hours. The test 
solution was carried out using culture medium 
containing 0.5% FBS. After incubation, the media 
is removed and washed with PBS 1 mL 1 times. Cell 
then treated with various concentration of PGB-0-F 
and doxorubicin for 24 and 48 hours. Estradiol was 
used as an induction of Matrix Metalloproteinases 
9 (MMP-9) expression. The 8% of SDS-PAGE 
supplemented with 0.1% of gelatin was used to 
determined the activity of MMP-9 in the culture 
medium. After electrophoresis, gels were washed 
and incubated with distilled water containing 2% 
of Triton-X 100 (Merck, Darmstadt, Germany) for 
30 minutes at room temperature. The solution was 
removed from gels. 100 mL of reaction buffer (40 
mM Tris-HCl pH 8, 10 mM CaCl2, 0.02% NaN3) 
was added and incubated for 24 hours at 37°C. 
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After removal of reaction buffer, gels were stained 
by Coomassie Brilliant Blue R-250 solution and 
destained by destaining solution (20% methanol, 
10% acetic acid and 70% water) until clear bands 
with dark blue background appear. The results were 
documented and analyzed by ImageJ software.
Data Analysis
 Scratch analysis was figured out by quantifying 
the cell migration distance using ImageJ software 
by comparing the distance between untreated and 
treated cells.  Data from multiple scratch within the 
same test group were analyzed using Analysis of 
Variance (ANOVA) test to analyze the difference 
between experimental group.   Data were presented 
as mean ± S.D. The p < 0.05 was considered 
statistically significant.  Gelatin Zymography data 
analysis was performed by comparing the intensity 
of the band treated cells to untreated cells using 
ImageJ software.
RESULTS
Anti-Migratory Effect of PGB-0-F on MCF-7/
HER2 Cells
 Examination After 42 hours of incubation, 
single PGB-0-F treatment with 15 μM concentration 
gave the smallest closure value (60%) when 
compared with the lower PBG-0-F treatment of 7.5 
μM (90%) and 3.75 μM ( 70%) (Fig. 2A). These 
results  suggest  that  high  concentrations  of  PGB-
0-F may  inhibit migration, but at low concentration 
will lead to an increase in MCF-7/HER2 cell 
migration .
 Single doxorubicin treatment showed 
migration induction, whereas a single PGB-0-F 
treatment of 3.75 μM and 15 μM concentrations 
showed a decrease in cell migration when compared 
with control. This suggests inhibition of migration 
by PGB-0-F depending on the concentration 
(Fig. 2B). In the combination of PGB-0-F and 
doxorubicin seen that the combination of both 
can inhibit cell migration. When compared with a 
single treatment of doxorubicin, PGB-0-F appears 
to  inhibit  cell  migration  caused   by  the  treatment 
of doxorubicin in MCF-7 / HER2 breast cancer 
cells.
Effect of PGB-0-F on MMP-9 Expression 
 The test results showed that MMP-9 expression 
significantly decreased by a single PGB-0-F 
treatment of 15 μM dosage either at 24 hours or 48 
hours (Fig. 3). This decrease in MMP-9 expression 
is even smaller when compared to cell control. In the 
treatment of PBG-0-F low concentrations of 3.75 
and 7.5 μM at 24 hours and 48 hours gave opposite 
results. This can be seen from the band's intensity 
which is thinner when compared to cell control. 
This indicates that MMP-9 expression is elevated 
in the low concentration PGB-0-F treatment but 
the increase in activity is still below that of a single 
doxorubicin treatment.
 MCF-7/HER2 cells were given estradiol 
treatment to increase their metastasis ability, then be 
treated with doxorubicin and PGB-0-F. At 24 hours 
and 48 hours the combination of PGB-0-F 3.75 
μM with doxorubicin led to an increase in MMP-
9 expression and higher than a single doxorubicin 
treatment. However, the combination of PGB-0-F 
with doxorubicin at higher concentration resulted 
in decreased MMP-9 activity. Based on the results 
obtained, the possible combination of PGB-0-F 
with doxorubicin could decrease the expression of 
MMP-9 induced by doxorubicin.
DISCUSSION
 In this present study, we observed the 
inhibition of cancer cell migration as the one of 
parts of metastasis process by treatment of PGB-
0-F through scratch wound healing assay. Based 
on the percent graph of MCF-7/HER2 cell closure 
(Figure 2A) PGB-0-F single treatment showed a 
decrease in cell movement at concentrations of 3.75 
μM and 15 μM. The treatment of PGB-0-F with 
concentration 15 µM has demonstrated highest 
migration inhibitory with % closure only 60% 
compare to the all treatment. 
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Figure 2. Effect of Single Treatment of PGB-0-F and its Combination with Doxorubicin on MCF-7/HER2 Cells 
Migration. A: The morphology of the cells after scratch and treated with 10 nM doxorubicin, 3.75; 7.5 and 15 μM PG-
B-0-F and their combination. Observations were made after 0, 18, 24 and 42 hours of treatment under an inverted 
microscope with magnification of 100x. B: The percentage of MCF-7/HER2 cells closure after 42 hours of treat-
ment. The area of the scratch were analyzed using ImageJ software then % closure was calculated in accordance 
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Figure 3. Effect of single treatment of PGB-0-F and its combination with Doxorubicin in MMP-9 activity on MCF-7/
HER2 Cells. Cell were treated with 10 nM Doxorubicin, 3.75 µM, 7.5 µM, 15 µM PGB-0-F, and their combination for 
24 and 48 hours. MMP-9 assay was conducted using gelatine zymography according to the method. Analysis of the 
result were done by using ImageJ software to measure the intensity of gelatin degradation by MMP-9 in the gel.
 Doxorubicin is a chemotherapy that is 
widely used in cases of breast cancer. Doxorubicin 
occupies the main chemotherapy in the treatment of 
breast cancer, especially breast cancer with positive 
HER2 (American Cancer Society, 2006). In the 
treatment of doxorubicin acts both in the adjuvant or 
neoadjuvant parts along with other types of therapy. 
Recent study revealed doxorubicin at concentration 
of 10 nM is known to induce migration by induce 
the formation of lamelipodia but does not affect the 
proliferation of breast cancer cells 4T1 and MCF-
7/HER2 (Amalina, et al., 2017). This result in this 
study on a significant increase of cell movement 
compared to control cells with % closure up to 
90%. Furthermore the combination of PGB-0-F 
with doxorubicin gave inhibitory results of cell 
migration when compared with a single treatment 
of doxorubicin. This result shows PGB-0-F is able 
to suppress the induction of migration caused by 
doxorubicin and can act as co-chemotherapy agent 
along with doxorubicin. This result also in line with 
previous study which showed that curcumin and its 
analogues (PGV-0 and PGV-0) can increased the 
sensitivity of MCF-7 breast cancer cells that have 
resistance with doxorubicin through HER2 and NF-
kB inhibition (Meiyanto, et al., 2014)
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 Normal cell migration is associated with 
excessive expression of extracellular matrix 
degrading proteins such as MMP-9. In the present 
study the MMP-9 expression was measured 
using gelatine zymography. The main principle 
of this method is to look at the ability of MMP-9 
to degrade gelatin added in the gel and to reveal 
a clear band to the gel. MCF-7/HER2 cells were 
given estradiol treatment to improve their metastatic 
ability. The 17β-estradiol compound (E2) is an 
estrogen hormone known to increase the ability of 
movement and invasion of breast cancer cells by 
activating ezrin actin-binding protein (Zheng, et al., 
2011). The treated E2 cells were then given a single 
PGB-0-F treatment, doxorubicin and a combination 
of both.
 At a single treatment E2 hours 24 and 48 
appear to increase MMP-9 expression as compared 
to cell control. In addition, an increase in MMP-
9 expression was also seen in the treatment of 
doxorubicin especially at 48 hours. At a single 
24-hour PGB-0-F treatment can decrease MMP-
9 expression in line with increasing dosage. 
In combination PGB-0-F and doxorubicin the 
MMP-9 expression also decreased and looked 
like a combination of PGB-0-F with doxorubicin 
mutually impeding MMP-9 enhancement by both. 
Particularly in the treatment of PGB-0-F 15 μM 
concentration with doxorubicin decreased MMP-
9 expression was lower when compared with cell 
control and single treatment of both compounds. 
While in the 48-hour treatment PGB-0-F single 
treatment also increased the expression of MMP-9 
higher  than  the  treatment  of  doxorubicin  along 
with increased concentration. The combination 
of PGB-0-F  treatment with doxorubicin also 
increased MMP-9 expression when compared with 
the second single treatment. These results show 
that in  48  hours  treatment  the  combination  of 
PGB-0-F concentrations of 3.75 μM, 7.5 μM and 15 
μM  with  doxorubicin  actually  increased  MMP-9 
expression.
 The migration test and MMP-9 expression 
were carried out at 24 hours and 48 hours because 
to see whether the treatment with PGB-0 could 
have a good effect on the condition before doubling 
time of MCF-7/HER2 cells or when the cell had 
proliferated. The increase in MMP-9 expression 
at 48 hours is thought to be due to doubling time 
and increasing number of cells, causing MMP-9 
expression to increase. This can be seen with an 
increase in MMP-9 expression in each treatment. 
However, this increase can be overcome by a 
decrease in MMP-9 expression which is in line 
with the increase in concentration, especially in 
combination treatment. This is what explains if the 
PGB-0-F treatment combination with doxorubicin 
can reduce MMP-9 expression.
 In the migration test, cell migration was 
increased in line with increasing concentrations in 
the PGB-0-F single treatment. Particularly for the 
treatment of PGB-0-F the concentration of 7.5 μM 
was seen to increase cell migration significantly when 
compared to cell control. Whereas in the combined 
treatment of migration results also increased when 
compared with control cells, but decreased when 
compared with single doxorubicin treatment. This 
suggests that the combination of PGB-0-F with 
doxorubicin gives a positive effect, i.e., each drug 
is able to negate the migration effect caused by the 
second single treatment. However, the MMP-9 test 
results show a decrease in MMP-9 expression in 
line with increasing concentrations in both single 
and combination treatments. This result is different 
from the results on the migration test. Decreased 
expression of MMP-9 indicates a decreased ability 
of cancer cell migration. However, in the present 
study migration persists even though MMP-9 
expression decreases. It is possible that inhibition 
of migration by a combination of doxorubicin and 
PGB-0-F in MCF-7/HER2 cells is not through 
decreased MMP-9 expression, but through other 
pathways such as affecting the dynamics of actin 
cytoskeleton via RAC1 pathway (Welf and Haugh, 
2011; Amalina, et al., 2016).
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CONCLUSION
 PGB-0-F exhibits anti-migration effect against 
doxorubicin treatment and also inhibits MMP-9 
alone and combination with doxorubicin on MCF-
7/HER2 cells. 
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